
    
      Healthy children were randomized and received a single dose of either MenACYW Conjugate
      vaccine or MENVEOÂ®. They were assessed for immunogenicity at baseline (pre-vaccination) and
      at 30-44 days post-vaccination. Safety information were collected post-vaccination and
      throughout the entire study.
    
  